Popular topics to explore
Alembic Pharma Unit Clears US FDA Inspection Cleanly
APLLTD : Alembic Pharmaceuticals’ Bioequivalence Facility in Gujarat has successfully completed a US FDA inspection with zero observations. The inspection was conducted over 11 days from August 31 to September 10, 2026. The US FDA issued F…
Alembic Pharma Delivers Strong Revenue Growth in Q1FY27
💊 APLLTD reported Q1FY27 consolidated net profit of ₹170 crore, up from ₹154 crore in the corresponding quarter last year. Revenue increased sharply to ₹2,150 crore from ₹1,710 crore, while the EBITDA margin softened to 15.44% from 16.45%…
29th Jul · SEBI Registration INH000018142
SEBI Registration INH000018142 · 29th Jul
Alembic Pharma Receives USFDA Approval for Generic Prucalopride Tablets
Alembic Pharmaceuticals Ltd. has bolstered its presence in the U.S. healthcare market after securing final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for generic prucalopride tablets in 1 mg and 2 mg dosages. Th…
Update for investors of APLLTD
APLLTD is currently trading at Rs. 818.75, up by 4.30 points or 0.53% from its previous closing of Rs. 814.45 on the BSE.
The scrip opened at Rs. 814.45 and has touched a high and low of Rs. 828.70 and Rs. 812.90 respectively. So far 649…
28th Jul · SEBI Registration INH000009685
SEBI Registration INH000009685 · 28th Jul
ALEMBIC PHARM : Alembic Pharmaceuticals Limited receives USFDA Final Approval for Prucalopride Tablets, 1 mg and 2 mg.
APLLTD
Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval
from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application
(ANDA) Prucalopride Tablets, 1 mg and 2 mg. The a…
💊 USFDA Nod Boosts APLLTD 's US Growth
Alembic Pharmaceuticals has secured final USFDA approval for its Prucalopride Tablets (1 mg & 2 mg), a generic version of Takeda’s Motegrity, used to treat chronic idiopathic constipation (CIC) in adults. 📌 Addressable market: US$100 mill…
Update for investors of APLLTD
APLLTD is currently trading at Rs. 829.25, up by 3.90 points or 0.47% from its previous closing of Rs. 825.35 on the BSE.
The scrip opened at Rs. 834.60 and has touched a high and low of Rs. 837.55 and Rs. 828.80 respectively. So far 166…
19th Jul · SEBI Registration INH000020466
SEBI Registration INH000020466 · 19th Jul
Alembic Pharmaceuticals & NATCO Receive Tentative USFDA Approval for Olaparib Tablets
Alembic Pharmaceuticals, in partnership with NATCO Pharma Limited, has received tentative approval from the USFDA for Olaparib Tablets (100 mg and 150 mg). The product is therapeutically equivalent to AstraZeneca’s reference drug, Lynparza.…
Alembic Pharma in Focus: USFDA Warning Letter Puts Stock Under Spotlight Today
APLLTD is likely to remain in focus today after the USFDA issued a warning letter to the Clinical Investigator linked to a bioequivalence study conducted at the company's bioequivalence facility. The inspection took place between March 3…
RECLTD
### Stocks in Focus
** RECLTD ** & **PFC** – The boards of REC and PFC have approved the proposed merger scheme, a move aimed at creating a stronger, larger power sector financing institution with improved operational efficiencies. *(Po…
APLLTD Downtrend
APLLTD The stock continues to trade within a well-defined descending channel, with the falling trendline acting as a persistent resistance zone for nearly a year. until the trendline is convincingly breached, rallies are likely to be treat…
Update for investors of APLLTD
APLLTD is currently trading at Rs. 743.90, up by 8.90 points or 1.21% from its previous closing of Rs. 735.00 on the BSE.
The scrip opened at Rs. 737.15 and has touched a high and low of Rs. 750.65 and Rs. 737.15 respectively. So far 341…
TCS
## TCS ### launches India’s first Oracle AI Data Platform Lab in Kolkata. (Positive)
## SBIN & BANKBARODA ## plan first dollar bonds under RBI subsidy window. (Positive)
## NLCINDIA ## secures a critical mineral block in Telangan…
Alembic Pharma Moves Closer to Potential 180-Day US Market Exclusivity with Cancer Drug Approval
Alembic Pharmaceuticals Ltd. (APLLTD) has received tentative approval from the USFDA for its generic version of Larotrectinib Capsules in 25 mg and 100 mg strengths, a drug used to treat certain adult and pediatric patients with solid tumo…
Alembic Pharma Eyes Global Growth with Strategic Canada Bet
APLLTD is likely to remain in focus on 8 June 2026 after announcing a strategic move to strengthen its international footprint. The company has signed a Shareholders' Agreement to acquire a 45% stake in a newly incorporated Canadian corpo…
Indian markets are set for a sharp gap-down opening today
🌍 Global Market Update US indices (June 7 close): Nasdaq -4.18% (25,709), S&P 500 -2.64% (7,383), Dow -1.35% (50,867). Europe (last close): DAX -1.25%, CAC -0.71%, FTSE -0.34%. Commodities: Brent crude ~$96.4 (+2.5%), WTI ~$92.7 (+2.3%)…
Update for investors of APLLTD
APLLTD is currently trading at Rs. 755.85, up by 8.20 points or 1.10% from its previous closing of Rs. 747.65 on the BSE.
The scrip opened at Rs. 747.70 and has touched a high and low of Rs. 760.10 and Rs. 745.95 respectively. So far 480…
15th May · SEBI Registration INH000016074
SEBI Registration INH000016074 · 15th May
Alembic Pharma Q4 Profit Rises 25% YoY, Margins Under Pressure
APLLTD
📰 Key Highlights
Net Profit: ₹2B vs ₹1.6B YoY → +25% growth
Revenue: ₹18.5B vs ₹17.7B YoY → +5% growth
EBITDA: ₹2.3B vs ₹2.73B YoY → -16% decline
EBITDA Margin: 12.34% vs 15.4% YoY → margin contraction of ~306 bps
🔎 Fundamen…
Stocks in news today
PREMIERENE s has launched India’s first All-Black G12R DCR Solar Module--the NeoBlack Series at RenewX Chennai, marking a significant step in redefining rooftop solar for residential and commercial segments through design-led innovation. T…
Alembic Pharma Gains USFDA Nod, Eyes $145 Million Opportunity in US Market
APLLTD has secured final approval from the US Food and Drug Administration (USFDA) for its Fingolimod Capsules (0.5 mg), a generic version of Gilenya used to treat relapsing forms of multiple sclerosis in patients aged 10 years and above.…
